Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2025 08:32 ET | Source: Noom Inc

Noom To Streamline Access to Zepbound® Vials with Noom GLP-1 Companion Through Integration with LillyDirect® Pharmacy Provider

Noom announced an agreement with Eli Lilly and Company’s LillyDirect® pharmacy provider, Gifthealth, streamlining access to Zepbound® vials for members.
March 24, 2025 08:31 ET | Source: Sesame

Sesame, America’s Low-Cost Leader in Healthcare, Streamlines Access for Eligible Patients to Lilly’s Obesity Medicine Zepbound

NEW YORK CITY, March 24, 2025 (GLOBE NEWSWIRE) -- Sesame, the company that offers Americans quality, convenient health care at half the typical price, today announced a technical integration with...
February 13, 2025 11:55 ET | Source: Spherix Global Insights

Early Launch Metrics Indicate UCB’s Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthritis Market

EXTON, PA, Feb. 13, 2025 (GLOBE NEWSWIRE) -- UCB’s Bimzelx (bimekizumab) is making a strong entrance into the U.S. psoriatic arthritis (PsA) market, with early indicators suggesting it could drive a...
January 31, 2025 13:52 ET | Source: Spherix Global Insights

FDA Approval of Eli Lilly’s Omvoh for Crohn’s Disease Adds a New Option, but Uptake May be Hampered by US Gastroenterologists’ Brand Preferences Among the IL-23 Class, According to Spherix Global Insights

EXTON, PA, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The FDA's approval of Eli Lilly’s Omvoh for Crohn’s disease marks a significant milestone as the therapy becomes the second IL-23 inhibitor available for...
October 28, 2024 08:00 ET | Source: ViaNautis Bio

ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines

ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines Multi-year collaboration will use...
October 28, 2024 03:00 ET | Source: ViaNautis Bio

ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines

ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines Multi-year collaboration will use...
October 21, 2024 17:10 ET | Source: Mangoceuticals, Inc.

MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly

Dallas, Texas, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness...
October 01, 2024 10:51 ET | Source: Spherix Global Insights

Exciting Advances in Ulcerative Colitis Treatments: Skyrizi Gains Early Momentum Following FDA Approval in June

EXTON, PA, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The past twelve months have been transformative for the rapidly evolving ulcerative colitis (UC) market, with a surge in advanced therapies receiving FDA...
September 09, 2024 10:20 ET | Source: Spherix Global Insights

The Highly Anticipated FDA Approvals of Galderma’s Nemolizumab and Eli Lilly’s Lebrikizumab are Expected to Shift Dermatologists’ Perceptions of the Atopic Dermatitis Market

EXTON, PA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Since its 2017 debut as the first advanced systemic treatment for atopic dermatitis (AD), Sanofi/Regeneron’s Dupixent has dominated the US market....
July 31, 2024 09:15 ET | Source: Wohl & Fruchter LLP

MORF Alert: Wohl & Fruchter LLP Files Class Action Lawsuit on Behalf of Shareholders of Morphic Holding, Inc., in the U.S. District Court for the Northern District of California

We have filed a class action lawsuit on behalf of Morphic shareholders alleging securities claims in connection with the proposed sale to Eli Lilly.

Next Page keyboard_arrow_right